

Amendments to the Claims:

Please amend claims 1 and 2 and cancel claims 55 and 56.

This listing of claims will replace all prior versions, and listings, of claims in the application.

In the Claims:

1. (Currently amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier, wherein said composition comprises:

a therapeutically effective amount of an extracellular matrix-binding fragment of Ang-1 protein ~~selected from the group~~ consisting of SEQ ID NO:1, ~~SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4~~, and/or a vector comprising a nucleic acid molecule that comprises the nucleotide sequence that encodes an extracellular matrix-binding fragment of Ang-1 protein ~~selected from the group~~ consisting of SEQ ID NO:1, ~~SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4~~.

2. (Currently amended) The pharmaceutical composition of claim 1 comprising a therapeutically effective amount of an extracellular matrix-binding fragment of Ang-1 protein ~~selected from the group~~ consisting of SEQ ID NO:1, ~~SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4~~.

3-18. (Canceled)

19. (Previously presented) A pharmaceutical composition comprising
a pharmaceutically acceptable carrier and
a therapeutically effective amount of a mutant Ang-1 having angiogenesis promoting activity but which have reduced or inactive extracellular matrix-binding.

20-25. (Canceled)

26. (Previously presented) A pharmaceutical composition comprising
a pharmaceutically acceptable carrier and
a therapeutically effective amount of a mutant Ang-1 having angiogenesis promoting activity but which is not cleaved into a antagonist fragment.

27-52. (Canceled)

53. (Previously presented) A pharmaceutical composition comprising
a) a pharmaceutically acceptable carrier and
b) a therapeutically effective amount of an Ang-1 fragment with antagonist activity.

54. (Previously presented) The pharmaceutical composition of claim 53 further comprising Ang-2 protein.

55-80. (Canceled)